
The team believe new therapies could be discovered and implemented before a vaccine becomes widely available by repurposing medicines for other conditions that are already in clinical use or are currently being tested.
STOPCOVID
The new project – STOPCOVID – will focus on the inflammatory pathways that lead directly to lung injury, which is associated with the most severe aspects of Covid-19.
Inflammation is important in fighting infection but in the case of Covid-19 excessive inflammation is causing the lungs to fail, leading to death.
Researchers will test drugs to see if they can block this and other damaging types of inflammation in the early stages of the disease to change the course of infection and prevent the need of a ventilator.
STOPCOVID has secured £2 million funding from LifeArc, a medical research charity, with its Centre for Diagnostics Development based at Edinburgh BioQuarter. Baillie Gifford, an investment firm, has also agreed to provide funding for the project.
The team aims to raise a total of £15 million from the private sector. Discussions are continuing with other potential partners.
The team are collaborating with pharmaceutical companies from across the world and have already identified key drugs and mechanisms that are currently in development or are being used for other diseases.